#United States #Los Angeles #Nordic Pharma #LACRIFILL #Dry Eye

Nordic Pharma Presents LACRIFILL® at the ASCRS Annual Meeting

Introduction
Nordic Pharma, a subsidiary of Nordic Group B.V., is set to present new data on its innovative treatment for dry eyes, LACRIFILL® Canalicular Gel, at the upcoming annual meeting of the American Society of Cataract and Refractive Surgery (ASCRS) in Los Angeles. This meeting, taking place from April 25 to April 28, 2025, serves as a crucial platform for ophthalmologists and researchers to share advancements in eye care.

Patient Study Presentation
During the ASCRS meeting, Nordic Pharma will unveil recently published patient data, as well as insights from an experience study involving the use of LACRIFILL®. The clinical outcomes show significant improvements in patients suffering from dry eyes, highlighting how this gel therapy can drastically enhance visual acuity and optical quality, particularly in individuals facing fluctuating vision post-cataract surgery.

Neel Desai, MD, and Subhashini Chandrasekaran, MD, are among those sharing a compelling case study titled "Improved Visual Outcomes With LACRIFILL® Canalicular Gel-Assisted Ocular Surface Optimization," which will be featured in the April edition of Cataract & Refractive Surgery Today. This study exemplifies the gel's effectiveness in treating dry eye symptoms through enhanced lacrimal occlusion.

Survey Insights
In addition to the case studies, May's edition of Cataract & Refractive Surgery Today will reveal the findings of a patient experience survey targeting doctors who utilized LACRIFILL® for the first time versus those familiar with its application. Remarkably, 98.11% of surveyed medical professionals expressed intentions to re-administer this therapeutic gel, confirming its favorable reception among practitioners.

Expert Insights
Jai Parekh, MD, MBA, the Commercial Director at Eye Care U.S., conveys his enthusiasm about the feedback and research presented a year after LACRIFILL® was first launched at ASCRS 2024. He states, “We have compelling evidence from case studies and patient experiences that affirm how LACRIFILL® Canalicular Gel enhances dry eye management, positively affecting both clinical practice and patient lifestyles.”

Furthermore, Priya Mathews, MD, of the Center for Sight, is excited to discuss her clinical insights and the tangible benefits of incorporating LACRIFILL® into practice. She emphasizes the potential for practitioners to adopt the role of “Lacrifillers,” which speaks to the innovative application of this gel therapy in everyday practice.

Community Engagement
Visitors to Nordic Pharma's booth (#717) at the ASCRS will not only learn more about LACRIFILL® but also engage in meaningful community involvement. In support of recent firefighting efforts in California, Nordic Pharma has implemented a QR code donation initiative at their booth to contribute to the Los Angeles Fire Department Foundation, with a portion of proceeds matched by the company.

Conclusion
In summary, Nordic Pharma, Inc. will bring forward pioneering developments regarding LACRIFILL® Canalicular Gel at the ASCRS Annual Meeting, demonstrating its valuable role in improving the visual health of patients experiencing dry eye symptoms. Those interested in the product can visit lacrifill.com for more information and ordering details.

About Nordic Group B.V.
Nordic Group B.V. is an international mid-sized pharmaceutical firm dedicated to developing and marketing specialized products. Its strategic acquisitions and innovations lay the groundwork for advancements in eye care, rheumatology, and women’s health, with recent expansions beyond Europe.

Contact Information
For further inquiries, please contact:
Kate Popova, Project and Contracts Manager
Phone: 610-285-1699
Email: [email protected]
Gail Feerrar, Sales and Marketing Director
Phone: 610-285-7152
Email: [email protected]